We are considering moving to a stable cell line for our lentiviral production, do you have advice on transfection vs. producer cell line?
This question is part of the following Ask The Expert session:
Answered by:
Company: MilliporeSigma
Job Title: Head of Technical Operations, Viral and Gene Therapy Manufacturing
Answer
While we see the future of LV manufacturing is moving towards the use of a stable cell lines, mainly due to reduction of costs of reagents required for the plasmid/transfection methods currently being used, the length of time (>1 year) to develop such lines and the lower productivity of such systems are the main current hurdles. Transfection based manufacturing process allows one to develop and manufacture in a few weeks time allowing one to test and get their therapeutic product into the pre-clinical and clinical environment much quicker.
This post is sponsored by MilliporeSigma.